Maze Therapeutics (MAZE) Income from Continuing Operations (2024 - 2026)
Maze Therapeutics recorded quarterly Income from Continuing Operations of 24208000.0 in Q1 2026, up 29.97% quarter-over-quarter from 34568000.0 in Q4 2025, and up 26.16% year-over-year from 19187783.77 in Q1 2025.
Maze Therapeutics' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 24208000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 26.16% year-over-year to 24208000.0; the TTM figure through Mar 2026 stood at 122542000.0 (down 336.18% YoY), while the FY2025 annual figure was 131120000.0, down 351.17% from the prior year.
- Income from Continuing Operations came in at 24208000.0 for Q1 2026 at Maze Therapeutics, up from 34568000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 139056000.0 in Q2 2024 to a low of 34568000.0 in Q4 2025.
- A 3-year average of 10932222.22 and a median of 29654000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 124.22% in 2025 and gained 26.16% in 2026, its largest moves.
- Maze Therapeutics' Income from Continuing Operations stood at 29654000.0 in 2024, then decreased by 16.57% to 34568000.0 in 2025, then rose by 29.97% to 24208000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 24208000.0, 34568000.0, and 30087000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn | -24.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.21 Mn |
| Dec 31, 2025 | -34.57 Mn |
| Sep 30, 2025 | -30.09 Mn |
| Jun 30, 2025 | -33.68 Mn |
| Mar 31, 2025 | -32.79 Mn |
| Dec 31, 2024 | -29.65 Mn |
| Sep 30, 2024 | -24.73 Mn |
| Jun 30, 2024 | 139.06 Mn |
| Mar 31, 2024 | -27.73 Mn |